

- **Name:** Min Hwan Kim
 - **Current Position & Affiliation:** Clinical Assistant Professor, Yonsei University
College of Medicine
 - **Country:** Korea
-

• **Educational Background:**

2003.3 ~ 2009.2 M.D., Yonsei University College of Medicine, Seoul, Korea

2012.3 ~ 2014.2 M.S., Department of Medicine, Yonsei University College of Medicine

2014.3 ~ 2017.9 Ph.D. Graduate School of Medical Science and Engineering, KAIST,
Daejeon, Korea

• **Professional Experience:**

2019.03~ 2020.02 Clinic Professor, Division of Medical Oncology, Department of
Internal Medicine, Yonsei Cancer Center, Yonsei University
College of Medicine

2020.03~2025.02 Clinical Assistant Professor, Division of Medical Oncology,
Department of Internal Medicine, Yonsei Cancer Center, Yonsei
University College of Medicine

2025.03~current Associate Professor, Division of Medical Oncology,
Department of Internal Medicine, Yonsei Cancer Center, Yonsei
University College of Medicine

• **Professional Organizations:**

Member of KSMO, KCA, and KCSG

Active member of AACR

Member of ASCO

Member of KOGO

• Main Scientific Publications:

Sanghyun Park#, Won-Ji Ryu #, Tae Yeong Kim, Yumi Hwang, Hyun Ju Han, Jeong Dong Lee, Gun Min Kim, Joohyuk Sohn, Sang Kyum Kim, **Min Hwan Kim ***, Joon Kim * Exp Mol Med. 2024 Apr;56(4):987-1000. doi: 10.1038/s12276-024-01210-5. Epub 2024 Apr 16. Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

Kim MH, Kim GM, Ahn JM, Ryu WJ, Kim SG, Kim JH, Kim TY, Han HJ, Kim JY, Park HS, Park S, Park BW, Kim SI, Jeong J, Lee J, Paik S, Kim S, Jung KH, Cho EH, Sohn J. Copy number aberrations in ctDNA enables prognosis prediction and molecular characterization of breast cancer. J Natl Cancer Inst. 2023 May 11:djad080. doi: 10.1093/jnci/djad080.

JG Yoon*, **MH Kim***, M Jang*, H Kim, HK Hwang, CM Kang, WJ Lee, B Kang, C Lee, MG Lee, HC Chung, HJ Choi, YN Park, Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses, Hepatology, 2021 Apr 21. doi: 10.1002/hep.31862 ***co-first authors**

Seo J*, **Kim MH***, Hong H, Cho H, Park S, Kim SK, Kim J. MK5 regulates YAP stability and is a molecular target in YAP-driven cancer, Cancer Res. 2019 Dec 15;79(24):6139-6152. doi: 10.1158/0008-5472.CAN-19-1339.cers. ***co-first authors**

Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, Shin EC, Kim J. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018 Jan 30

Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J, Actin Remodeling Confers BRAF Inhibitor Resistance to Melanoma Cells through YAP/TAZ Activation, The EMBO Journal 2016 Mar 1;35(5):462-78 (Journal Cover)